By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics outfit IntegraGen, the French National Institute for Health and Medical Research (INSERM), and its technology transfer subsidiary, INSERM Transfert, announced on Tuesday an agreement granting IntegraGen an exclusive worldwide option to license a portfolio of biomarkers for hepatocellular carcinoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.